Related Experiment Video
Updated: Jan 2, 2026
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Hyperkalemia in heart failure
Kiran Sidhu1, Rohan Sanjanwala, Shelley Zieroth
1Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Insights
New therapies, patiromer and sodium zirconium cyclosilicate (SZC), effectively manage hyperkalemia in heart failure patients. These treatments enable optimal use of renin-angiotensin-aldosterone (RAAS) inhibitors, improving patient outcomes.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hyperkalemia is common in heart failure patients, often linked to diabetes and chronic kidney disease.
- Renin-angiotensin-aldosterone (RAAS) inhibitors are crucial for heart failure management but can exacerbate hyperkalemia.
- Limited effective and tolerable treatments for hyperkalemia have hindered RAAS inhibitor therapy.
Purpose of the Study:
- To review novel therapies for hyperkalemia in heart failure patients.
- To evaluate the role of patiromer and sodium zirconium cyclosilicate (SZC) in managing hyperkalemia.
- To discuss the impact of these new agents on RAAS inhibitor therapy.
Main Methods:
- Review of clinical studies on patiromer and SZC in heart failure.
- Analysis of efficacy in maintaining normokalemia and safety profiles.
- Assessment of onset of action for acute hyperkalemia treatment.
Main Results:
- Patiromer and SZC effectively maintain normal potassium levels in heart failure patients.
- These agents offer improved side effect profiles compared to older potassium binders.
- SZC demonstrates rapid action for acute hyperkalemia management.
Conclusions:
- Patiromer and SZC are valuable additions to managing heart failure patients with hyperkalemia.
- These therapies facilitate sustained use and dose optimization of RAAS inhibitors.
- Improved hyperkalemia control allows for better guideline-directed medical therapy implementation.
Purpose Of Review:
Hyperkalemia is increasingly prevalent in the heart failure population as more people live with heart failure and comorbid conditions such as diabetes and chronic kidney disease. Furthermore, renin-angiotensin-aldosterone (RAAS) inhibitors are a key component of clinical therapy in these populations. Until now, we have not had any reliable or tolerable therapies for treatment of hyperkalemia resulting in inability to implement or achieve target doses of RAAS inhibition. This review will focus on two new therapies for hyperkalemia: patiromer and sodium zirconium cyclosilicate (SZC).
Recent Findings:
Patiromer and SZC have been studied in heart failure and both agents have demonstrated the ability to maintain normokalemia for extended periods of time with improved side effect profiles than existing potassium binders such as sodium polystyrene sulfate, though no direct comparisons have occurred. SZC has also shown promise in the treatment of acute hyperkalemia with its quick onset of action.
Summary:
Patiromer and SZC will be useful adjuncts in the clinical care of heart failure patients with hyperkalemia. These agents will allow clinicians to maintain patients on RAAS inhibitors and uptitrate their guideline directed medical therapy to target doses without the additional concern for recurrent hyperkalemia and its untoward effects.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:29Heart Failure II: Pathophysiology
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System